Skip to content
value.today

THRESHOLD Pharmaceuticals Inc.

Total raised
$110 M
4 rounds on record
Latest round
$20 M
Jul 2023
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of THRESHOLD Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$20 MNo. 4$10 to $50 million

THRESHOLD Pharmaceuticals Inc.: Raise no. 4, Jul 2023

Investors in this round

19 investors had bought by the notice of Jul 31, 2023: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $91 M offered; $71 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$2,700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric E. Poma · Executive Officer, Director
  • Jason E. Kim · Executive Officer
  • Roger J. Waltzman · Executive Officer
  • Corsee E. Sanders · Director
  • David E. Hoffmann · Director
  • Gabriela E. Gruia · Director
  • Harold E. Selick · Director
  • Jonathan E. Lanfear · Director
  • Kevin E. Lalande · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Stifel, Nicolaus & Company, Incorporated (CRD 793) · New York, New YorkSold in CA, CT, MA, NY

Remarks in the notice

  • On the amounts: “Total offering amount includes the $0.125 per underlying share of common stock for warrants to purchase common stock to be issued in a second closing, assuming certain conditions are met, and the aggregate exercise price of such warrants.”

Signed by Eric E. Poma, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 31, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2019$15 MNo. 3$10 to $50 million

THRESHOLD Pharmaceuticals Inc.: Raise no. 3, Nov 2019

Investors in this round

1 investor had bought by the notice of Dec 3, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam D. Cutler · Executive Officer
  • Eric E. Poma · Executive Officer, Director
  • Jason S. Kim · Executive Officer
  • Roger S. Waltzman · Executive Officer
  • David R. Hirsch · Director
  • David R. Hoffmann · Director
  • Harold E. Selick · Director
  • Jonathan R. Lanfear · Director
  • Kevin M. Lalande · Director
  • Scott E. Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric E. Poma, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 3, 2019. Read the notice at the SEC.

equitySEC
Aug 2017$40 MNo. 2$10 to $50 million

THRESHOLD Pharmaceuticals Inc.: Raise no. 2, Aug 2017

Investors in this round

16 investors had bought by the notice of Aug 15, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S. Valacer · Executive Officer
  • Eric E. Poma · Executive Officer, Director
  • Jason S. Kim · Executive Officer
  • David R. Hirsch · Director
  • David R. Hoffmann · Director
  • Harold E. Selick · Director
  • Kevin M. Lalande · Director
  • Michael R. Broxson · Director
  • Scott E. Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jason Kim, President & COO. Source: SEC Form D and 1 amendment, newest notice filed Aug 15, 2017. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$35 MNo. 1$10 to $50 million

THRESHOLD Pharmaceuticals Inc.: Raise no. 1, Oct 2009

Investors in this round

47 investors had bought by the notice of Oct 15, 2009: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$1,736,429
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harold E. Selick · Executive Officer, Director
  • Joel A. Fernandes · Executive Officer
  • John G. Curd · Executive Officer
  • Mark D. Matteucci · Executive Officer
  • Stewart M. Kroll · Executive Officer
  • Bruce C. Cozadd · Director
  • David C. Hoffman · Director
  • Jeffrey W. Bird · Director
  • Wilfred E. Jaeger · Director
  • William A. Halter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, NySold in no state named
  • Reedland Capital Partners · broker-dealer Financial West Group (CRD 16668) · Mill Valley, CaSold in no state named

Signed by Harold A. Selick, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 15, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • THRESHOLD Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2023).

    SEC Form D · Jul 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2023

That is all the official record says: THRESHOLD Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of THRESHOLD Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 47 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by THRESHOLD Pharmaceuticals Inc.
NameRoleNamed in
Eric E. PomaExecutive officerJul 2023
Jason E. KimExecutive officerJul 2023
Roger J. WaltzmanExecutive officerJul 2023
Adam D. CutlerExecutive officerDec 2019
Jason S. KimExecutive officerDec 2019
Roger S. WaltzmanExecutive officerDec 2019
Eric S. RogersExecutive officerNov 2019
David S. ValacerExecutive officerAug 2017
Harold E. SelickExecutive officerOct 2009
Joel A. FernandesExecutive officerOct 2009
John G. CurdExecutive officerOct 2009
Mark D. MatteucciExecutive officerOct 2009
Stewart M. KrollExecutive officerOct 2009
Corsee E. SandersDirectorJul 2023
David E. HoffmannDirectorJul 2023
Eric E. PomaDirectorJul 2023
Gabriela E. GruiaDirectorJul 2023
Harold E. SelickDirectorJul 2023
Jonathan E. LanfearDirectorJul 2023
Kevin E. LalandeDirectorJul 2023
David R. HirschDirectorDec 2019
David R. HoffmannDirectorDec 2019
Jonathan R. LanfearDirectorDec 2019
Kevin M. LalandeDirectorDec 2019
Scott E. MorensteinDirectorDec 2019
Michael R. BroxsonDirectorAug 2017
Bruce C. CozaddDirectorOct 2009
David C. HoffmanDirectorOct 2009
Jeffrey W. BirdDirectorOct 2009
Wilfred E. JaegerDirectorOct 2009
William A. HalterDirectorOct 2009